Docoh
Loading...

Filter options loading...
Top filers
Top filing types
Recent filing years
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm … liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in: withdrawal
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless of merit … damages, reputational harm, diminished profits and future earnings, injunctions, requests for recall, seizure of products, total or partial suspension
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability … and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, injunctions
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in: withdrawal … and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, injunctions
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless of merit … , reputational harm, diminished profits and future earnings, injunctions, requests for recall, seizure of products, total or partial suspension of production
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm … . If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition
S-1
PCSA Processa Pharmaceuticals Inc
13 Dec 19
IPO registration
5:32pm
others. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm … funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm
10-K/A
2018 FY
PCSA Processa Pharmaceuticals Inc
5 Apr 19
Annual report (amended)
9:40pm
successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless
10-K
2018 FY
PCSA Processa Pharmaceuticals Inc
28 Mar 19
Annual report
5:25pm
successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless
  • 1